Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 4/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000300 | 0.78 | KCNH2 (0.42) | MAOBSCN9A | |
| SCHEMBL5214698 | 0.77 | DHFR (0.63) | MAOB | |
| SCHEMBL3906522 | 0.77 | MPO (0.43) | MAOB | |
| SCHEMBL1379497 | 0.75 | MAOB (1.00) | MAOBPARP10NR4A2MAOA | |
| SCHEMBL992837 | 0.75 | MAOB (1.00) | MAOBPARP10NR4A2 | |
| SCHEMBL29638127 | 0.75 | MAOB (1.00) | MAOBPARP10NR4A2MAOA | |
| SCHEMBL624562 | 0.75 | MAOB (0.62) | MAOBPARP10NR4A2 | |
| Hydrochloric Acid SCHEMBL21313331 | 0.74 | MAOB (1.00) | MAOBPARP10NR4A2 | |
| Hydrochloric Acid SCHEMBL2197705 | 0.74 | MAOB (1.00) | MAOBPARP10NR4A2MAOA | |
| SCHEMBL7499087 | 0.73 | LTA4H (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6335354-B2 | FOR TREATMENT OF NEURONAL DAMAGE FOLLOWING GLOBAL AND FOCAL ISCHEMIA, TREATMENT OR PREVENTION OF NEURODEGENERATIVE CONDITIONS SUCH AS AMYOTROPHIC LATERAL SCLEROSIS, TREATMENT OR PREVENTION OF DIABETIC NEUROPATHY | COCENSYS INC. | 2002-01-01 | — | — | US | claimed |
| US-20010044428-A1 | Aminopyridines and methods of using thereof | COCENSYS, INC. | 2001-11-22 | — | — | US | claimed |
| EP-1268427-A1 | AMINOPYRIDINES AND THEIR USE AS ANTICONVULSANTS AND SODIUM CHANNEL BLOCKERS | Cocensys, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6335354-B2 | FOR TREATMENT OF NEURONAL DAMAGE FOLLOWING GLOBAL AND FOCAL ISCHEMIA, TREATMENT OR PREVENTION OF NEURODEGENERATIVE CONDITIONS SUCH AS AMYOTROPHIC LATERAL SCLEROSIS, TREATMENT OR PREVENTION OF DIABETIC NEUROPATHY | COCENSYS INC. | 2002-01-01 | — | — | US | disclosed |
| US-20010044428-A1 | Aminopyridines and methods of using thereof | COCENSYS, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001074779-A1 | AMINOPYRIDINES AND THEIR USE AS ANTICONVULSANTS AND SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044428-A1 | Aminopyridines and methods of using thereof | CACNA1S, CACNA1D, CACNA1C | MAOB 1557/4885PARP10 4033/4885NR4A2 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.